Female Contraception - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H1 2017, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 6, 3, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Contraception - Overview
Female Contraception - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Contraception - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Contraception - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Agile Therapeutics Inc
Bayer AG
Evofem Inc
Hervana Ltd
Mithra Pharmaceuticals SA
Orbis Biosciences Inc
Teva Pharmaceutical Industries Ltd
Viramal Ltd
Female Contraception - Drug Profiles
(anastrozole + levonorgestrel) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dienogest + ethinyl estradiol) PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(drospirenone + estetrol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(estradiol acetate + segesterone acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-68693 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 SP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-20015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphora - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1007626 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
drospirenone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etonogestrel ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVE-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-003296 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0101255 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 for Fertility Control - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Progesterone Receptor for Fertility Control - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TV-46046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Contraception - Dormant Projects
Female Contraception - Discontinued Products
Female Contraception - Product Development Milestones
Featured News & Press Releases
Jun 27, 2017: Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla
Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal
Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study
May 12, 2017: Mithra to Initiate PK Study for Estelle
May 06, 2017: Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla at ACOG 2017
May 03, 2017: Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
Apr 27, 2017: Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Womens Health
Apr 11, 2017: Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
Mar 16, 2017: Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
Feb 07, 2017: Mithra Completes Recruitment For European Phase III Estelle Study
Jan 18, 2017: Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive
Nov 07, 2016: Agile Therapeutics Announces Completion of Subject Visits for Twirla Phase 3 SECURE Clinical Trial
Sep 23, 2016: Mithra Pharmaceuticals: Phase III Clinical Study for Estelle in US Launched with first Randomized Patient
Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68693
Jul 22, 2016: Green Light From FDA For The Launch Of Estelle (E4/Drsp) Phase III Study In The United States
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Female Contraception, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Female Contraception - Pipeline by Addex Therapeutics Ltd, H1 2017
Female Contraception - Pipeline by Agile Therapeutics Inc, H1 2017
Female Contraception - Pipeline by Bayer AG, H1 2017
Female Contraception - Pipeline by Evofem Inc, H1 2017
Female Contraception - Pipeline by Hervana Ltd, H1 2017
Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H1 2017
Female Contraception - Pipeline by Orbis Biosciences Inc, H1 2017
Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Female Contraception - Pipeline by Viramal Ltd, H1 2017
Female Contraception - Dormant Projects, H1 2017
Female Contraception - Dormant Projects, H1 2017 (Contd..1), H1 2017
Female Contraception - Discontinued Products, H1 2017